Harmony Biosciences Holdings, Inc.NASDAQ: HRMY

Harmony Biosciences To Report Second Quarter 2026 Financial Results On August 4, 2026

· Issued by Harmony Biosciences Holdings, Inc. via GlobeNewswire

Summary by 6ix AI

Harmony Biosciences Holdings, Inc., a pharmaceutical company focused on therapies for rare neurological diseases, will report second quarter 2026 financial results on Tuesday, August 4, 2026, before the open of the U.S. financial markets.

Key details

  • Harmony will host a conference call and webcast on August 4, 2026, at 8:30 a.m. ET to discuss the results.
  • Dial-in numbers are 800-347-6865 (domestic) or 203-518-9757 (international or alternate), with passcode HRMYQ226; callers are advised to dial in at least 10 minutes early.
  • A live and replay webcast will be available on the investor page of the company's website.

6ix AI wrote this summary from the release below and checked it against the release.

PLYMOUTH MEETING, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report second quarter 2026 financial results on Tuesday, August 4, 2026, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on August 4, 2026, at 8:30 a.m. ET to discuss the results.

To participate in the call, please dial 800-347-6865 (domestic) or 203-518-9757 (international or alternate), and reference passcode HRMYQ226. It is recommended that you dial in at least 10 minutes prior to the call.

The live and replay webcast of the call will be available on the investor page of our website at https://ir.harmonybiosciences.com/.

About Harmony Biosciences
Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. Driven by novel science, visionary thinking, and a commitment to those who feel overlooked, Harmony Biosciences is nurturing a future full of therapeutic possibilities that may enable patients with rare neurological diseases to truly thrive. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, Pa, we believe that when empathy and innovation meet, a better future can begin; a vision evident in the therapeutic innovations we advance, the culture we cultivate, and the community programs we foster. For more information, please visit www.harmonybiosciences.com.

Harmony Biosciences Investor Contact:
Brennan Doyle
484-566-3685
[email protected]

Harmony Biosciences Media Contact:
Cate McCanless
202-641-6086
[email protected]

Harmony Biosciences Holdings, Inc. on 6ix

Story so far

Earlier from Harmony Biosciences

Later from Harmony Biosciences

All Harmony Biosciences news releases